June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Evaluation of Potential Systemic Adverse Events Related to Fluorescein Angiography in Pediatric Patients
Author Affiliations & Notes
  • Ru-ik Chee
    Ophthalmology, Weill Cornell Medicine, New York, New York, United States
  • Mrinali P. Gupta
    Ophthalmology, Weill Cornell Medicine, New York, New York, United States
  • Anton Orlin
    Ophthalmology, Weill Cornell Medicine, New York, New York, United States
  • Irene Rusu
    Ophthalmology, Weill Cornell Medicine, New York, New York, United States
  • Samir N Patel
    Ophthalmology, Memorial Sloan Kettering Cancer Center, New York, New York, United States
  • Jung Hee Han
    Anesthesia, Weill Cornell Medicine, New York, New York, United States
  • Vivien Yap
    Pediatrics, Weill Cornell Medicine, New York, New York, United States
  • Karyn Elizabeth Jonas
    Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago, Illinois, United States
  • Michael F Chiang
    Ophthalmology, Casey Eye Institute, Oregon Health & Science University, Portland, Oregon, United States
  • Robison Vernon Paul Chan
    Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago, Illinois, United States
  • Footnotes
    Commercial Relationships   Ru-ik Chee, None; Mrinali Gupta, None; Anton Orlin, None; Irene Rusu, None; Samir Patel, None; Jung Hee Han, None; Vivien Yap, None; Karyn Jonas, None; Michael Chiang, Clarity Medical Systems (S), Novartis (C); Robison Chan, Alcon (C), Allergan (C), Bausch and Lomb (C), Visunex Medical Systems (C)
  • Footnotes
    Support  Unrestricted departmental funding from Research to Prevent Blindness (RIC, MPG, AO, KEJ, MFC, RVPC), NIH P30EY10572 (MFC)
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2431. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ru-ik Chee, Mrinali P. Gupta, Anton Orlin, Irene Rusu, Samir N Patel, Jung Hee Han, Vivien Yap, Karyn Elizabeth Jonas, Michael F Chiang, Robison Vernon Paul Chan; Evaluation of Potential Systemic Adverse Events Related to Fluorescein Angiography in Pediatric Patients. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2431.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Existing studies on fluorescein angiography (FA) safety primarily involve adults. Reported adverse effects of FA in adults include nausea, vomiting, urticaria, anaphylaxis and cardiac arrest, which usually manifest clinically <24 hours post-FA. This study aims to evaluate the systemic safety profile of intravenous fluorescein dye injection in pediatric patients.

Methods : A retrospective chart review of patients aged 0-18 years who underwent examination under anesthesia with FA between 2010 and 2015 was performed. Detailed intra- and peri-operative physiological parameters (Table 1) from Anesthesia Information Management System (AIMS) were reviewed. Data points in AIMS were generated every 15 seconds, other than systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean arterial pressure (MAP), which were generated every 150 seconds. Peri-injection effects of intravenous fluorescein were evaluated by two-tailed paired t-test comparison of mean five-minute pre-injection and five-minute post-injection AIMS data. Significant adverse events <24 hours after FA were evaluated by new documented skin rash, cardiorepiratory compromise, delay in extubation, or unexpected readmission in patients’ medical records.

Results : 85 visits by 65 patients were included. AIMS data was available for 70 of 85 visits. 27 visits had an exact documented time of fluorescein injection for comparison of mean five-minute pre- and post-injection physiological parameters: Heart rate (p=0.64), respiratory rate (p=0.34), MAP (p=0.74), SBP (p=0.65), DBP (p=0.93), oxygen saturation (p=0.38), tidal volume (p=0.64), peak inspiratory pressure (p=0.2), peak end-expiration pressure (p=0.18), sevoflurane rate (p=0.2), and end-tidal CO2 levels (p=0.63). One of 85 visits had significant medical events within 24 hours of FA. The apnea, bradycardia and desaturation experienced by this preterm infant after FA had also occurred prior to FA, and were not causally associated with FA. Mean age at time of FA of the patients included in the study was 2.52 years, with chronologic age range of 4 weeks (32 weeks postmenstrual age) to 16.2 years. Of all visits, most common diagnoses were retinopathy of prematurity (44.7%), Coat’s disease (8.2%), and familial exudative vitreoretinopathy (7.1%).

Conclusions : In this study, no significant systemic adverse events were found to be associated with intravenous FA in pediatric patients.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×